A quick-release formulation of bromocriptine [Cycloset] appears to be a promising new treatment modality for type 2 diabetes mellitus (T2DM)

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1655, 2008-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Quick-Release Bromocriptine for Treatment of Type 2 Diabetes

By  

Current Drug Delivery, Vol. 8, Iss. 5, 2011-09 ,pp. : 511-516

Bentham Science Publishers

Access to resources Recommend Favorite

Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes

By Scranton Richard   Cincotta Anthony  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 269-279

Informa Healthcare

Access to resources Recommend Favorite

The risk of developing type 2 diabetes mellitus (DM) appears to be significantly less among olanzapine recipients than clozapine recipients

By  

Reactions Weekly, Vol. 1, Iss. 1208, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

DM programme effective in type 2 diabetes mellitus

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 354, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Teglicar "promising tool" in type 2 diabetes mellitus

By  

Inpharma, Vol. 1, Iss. 1655, 2008-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite